NC
ABCL icon

nVerses Capital’s AbCellera Biologics ABCL Stock Holding History

nVerses Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,446
Closed -$121K – 349
2025
Q4 		$121K Buy
+35,446
New +$158K 0.27% 157
2024
Q2 		– Sell
-1,100
Closed -$4.98K – 981
2024
Q1 		$4.98K Buy
+1,100
New +$5.61K 0.01% 586

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

nVerses Capital's ABCL Position: Q1 2026 in Review

nVerses Capital sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 35,446 shares — an estimated $121K sold.

nVerses Capital first reported a position in ABCL in Q1 2024 and held it in 2 quarters. The position peaked at $121K in Q4 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • nVerses Capital reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • nVerses Capital sold 35,446 AbCellera Biologics shares in Q1 2026, an estimated $121K.
  • nVerses Capital first reported a position in AbCellera Biologics in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's AbCellera Biologics position peaked at $121K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on nVerses Capital's 13F filing for Q1 2026, filed 13 May 2026.